Indivior

Indivior Plc, founded in Chesterfield, Virginia, is a global medical organization dedicated to developing, manufacturing, and selling buprenorphine-based prescription drugs aimed at treating opioid dependence and co-occurring disorders. The company's core mission is to provide effective treatment options for opioid use disorder, addiction, and schizophrenia. Indivior's product lineup includes SUBLOCADE injection for subcutaneous use, SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in over 40 countries, focusing on addressing the global opioid crisis.

Notable individuals affiliated with Indivior include its experienced leadership team and board members who have extensive backgrounds in pharmaceuticals and healthcare. The company has attracted significant investment from stakeholders committed to combating the opioid epidemic. Key achievements include the successful market introduction of its flagship products, SUBLOCADE and SUBOXONE, which have become critical tools in opioid dependence treatment. Indivior's impact is profound, providing essential medications to millions globally and contributing to public health efforts to manage and reduce opioid addiction.